We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sight Sciences Inc (SGHT) USD0.001

Sell:$5.13 Buy:$5.15 Change: $0.14 (2.67%)
NASDAQ:2.05%
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$5.13
Buy:$5.15
Change: $0.14 (2.67%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$5.13
Buy:$5.15
Change: $0.14 (2.67%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.

Contact details

Address:
4040 Campbell Ave,, Suite 100
MENLO PARK
94025
United States
Telephone:
+1 (415) 8890550
Website:
https://www.sightsciences.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SGHT
ISIN:
US82657M1053
Market cap:
$266.60 million
Shares in issue:
49.55 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Paul Badawi
    President, Chief Executive Officer, Co-Founder, Director
  • David Badawi
    Co-Founder, Chief Technology Officer, Director
  • Alison Bauerlein
    Chief Financial Officer, Chief Accounting Officer, Treasurer
  • Sam Park
    Chief Operating Officer
  • Jeremy Hayden
    Chief Legal Officer
  • Matthew Link
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.